NCT02756039 is a clinical trial in All Patients Treated With the Product, sponsored by AstraZeneca.

Who is sponsoring NCT02756039?

NCT02756039 is sponsored by AstraZeneca.

What condition does NCT02756039 study?

NCT02756039 studies All Patients Treated With the Product.

Is NCT02756039 still recruiting?

NCT02756039 is currently completed. Last updated 28 August 2019.

Last reviewed 2019-08-28 · How we verify

NCT02756039

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)

Completed Last updated 28 August 2019

What this trial tests

trial in All Patients Treated With the Product in 3,494 participants. Completed in 31 August 2018.

Timeline

25 May 2016

Primary endpoint
31 August 2018

31 August 2018

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,494
Start date	25 May 2016
Primary completion	31 August 2018
Estimated completion	31 August 2018
Sites	47 locations across Japan

Conditions studied

All Patients Treated With the Product — all drugs for All Patients Treated With the Product →

Sponsor

AstraZeneca — full company profile →

Who can join

Eligibility, any sex, with All Patients Treated With the Product. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical experience investigation (CEI) is to be conducted to confirm the following to characterise safety and efficacy of Tagrisso Tablets in actual clinical use. 1. Incidence of adverse drug reactions (ADRs) in actual clinical use 2. Factors which may affect safety and efficacy of the product (especially analysis of the incidence and risk factors of interstitial lung disease (ILD) events) 3. Information of ADRs not expected from "Precautions for Use" of the package insert in Japan

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.
Ohe Y, Kato T, Sakai F, Kusumoto M, et al · · 2020 · cited 24× · PMID 32548617 · DOI 10.1093/jjco/hyaa067

Verify or expand the search:

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02756039 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 28 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02756039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing